Gonadotrofines en IUI moeten terugbetaald worden als eerstelijnsbehandeling bij Unexplained Infertility en Mild Male Subfertility  Thomas D’Hooghe, MD,

Slides:



Advertisements
Similar presentations
Ovarian Stimulation in IUI- Overview
Advertisements

IUI with gonadotrophins P Devroey Centre for Reproductive Medicine Dutch - speaking Brussels Free University Laarbeeklaan Brussels Belgium.
Ovarian Ageing and Fertility
 OHSS is a serious, potentially life- threatening, iatrogenic complication of “controlled” ovarian stimulation.  To optimize the ovarian response without.
Case History. Case #1 s 26 y/o P0010, previous SAB in 2 years’ trying s BMI 18.2, healthy habits, no comorbid conditions s Usual cycles days s Husband.
Shahar Kol, Maccabi Health Care Services Rambam Health Care Campus Technion, Israel Institute of Technology.
Elonva in poor responders
Intrauterine insemination: state of the art, 2004 Is new always better? B.J. Cohlen Isala Clinics Zwolle The Netherlands.
RECOMBINANT VS. URINARY FSH IN IUI J. Serna MD PhD.
Minimal Monitoring of Ovulation Induction (OI) Is It Safe? Mustafa Uğur Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, Turkey.
LIFE AFTER NEW IVF LEGISLATION IN TURKEY Hakan Ozornek, MD EUROFERTIL Istanbul.
Gonadotrophin-releasing hormone antagonists for assisted reproductive technology in women with poor ovarian response. Subgroup analysis of Cochrane systematic.
Infertility I. Fertility  BBT & Cervical Changes  Home Ovulation Prediction II. Causes of infertility  Male factor infertility  Tubal Infertility 
Dr H Faruk Buyru İÜ İstanbul Medical Faculty Dept of Obstet&Gynecol.
Female Age and Fertility Piedmont Reproductive Endocrinology Group PREG John E. Nichols, JR., M.D. John. F. Payne, M.D. March 2009.
Embryo Transfer: Practical Tips to Get Ready for Prime Time
The Effect of PCOS Treatment on Ovarian Function
SURGICAL TREATMENT OF PCOS SURGICAL TREATMENT OF PCOS Professor T C LI Professor of Reproductive Medicine & Surgery Sheffield.
Role of Anti-Mullerian hormone in prediction of Assisted Reproductive Technology outcomes Leili Safdarian M.D. Khadigeh Khosravi M.D. Marzieh Agha Hosseini.
IVM is ready as a treatment for PCOS patients
The outcome of oocyte freezing as compared with embryo freezing Filippo Maria Ubaldi M.D. M.Sc. CLINICA VALLE GIULIA, Rome 3° Congress of Society of Reproductive.
Discontinuation of rLH two days before hCG may increase the number of oocytes retrieved in IVF Jessica B Spencer 1*, Aimee S Browne 1, Susannah D Copland.
IUI INDICATIONS, OVARIAN STIMULATION PROTOCOLS CC, AROMATASE INHIBITORS, GONADOTROPINS Hakan Özörnek, MD EUROFERTIL İstanbul.
Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle.
The uses of antagonist in IVF/ICSI cycle Prof. Dr. Mohamed Said Elmahaishi Lamis IVF Centre Misurata/ Libya 5 th International Congress In Infertility.
Does exogenous LH activity influence the outcome in IVF and not in ICSI cycles? Peter Platteau, Johan Smitz, Carola Albano, Per Sørensen Joan-Carles Arce.
Safety and efficacy of FSH drugs in ART for polycystic ovarian disease M. Aboulghar Cairo, Egypt.
Optimal timing of IUI Tansu KÜÇÜK GATA ANKARA. Cx Px.
IUI A to Z. MethodPregnancy Rate (%) Intercourse (Timed)4 (Follicle Monitoring) 1 IUI6 ---do---- CC6 ---do---- CC+IUI8 2 FSH / HMG7.7 CC / FSH /IUI9-12.
TEMPLATE DESIGN © Oocyte donation outcomes at Alpha International Fertility Centre IntroductionResultsConclusions References.
Planning of GnRH antagonist cycles
Elective Single Embryo Transfer (eSET); How Much Reasonable ? Rifat H. Gürsoy,M.D. Gazi University School of Medicine Dept. Of Ob/Gyn Reproductive Endocrinology.
University Medical Centre Department for Reproductive Medicine Ljubljanska 5 SI-2000 Maribor Slovenia Accredited by EBCOG/ESHRE
The 4th Misurata scientific meeting of infertility Benghazi – Libya 10/10/2008 Dr. Omar A. Elsraiti Consultant of Obst. & Gyn. IVF Centre - Misurata /
TEMPLATE DESIGN © IMPACT OF SEXUAL ABSTINENCE DURATION ON ICSI OUTCOME May Kew Loke and Pak Seng Wong Sunfert International.
CONSENSUS ON INFERTILITY TREATMENT RELATED TO POLYCYSTIC OVARY SYNDROME Asc.Prof. Dr. Kazım GEZGİNÇ Konya University, Faculty of Meram Medicine, Department.
SL ‘00 Antagonists in patients with previous poor ovarian response Antagonists in patients with previous poor ovarian response Geoffrey H Trew Consultant.
Agonist vs Antagonist Dr. Milton Leong.
Recommended Dosage of GnRH Antagonist is Too High Presented by Dr. Milton Leong, MD DSc(McGill) Director, IVF Centre.
A review on the luteal phase P Devroey MD PhD Centre for Reproductive Medicine Dutch-speaking Brussels Free University Brussels - Belgium.
Clinical Trials – Human Gonadotropin Drug Products A Regulatory Perspective Shelley R. Slaughter, M.D., Ph. D. Reproductive Medical Officer Team Leader.
IUI 2011 Prof. Dr. Esat ORHON 1. Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine.
PCOS and Infertility Treatment
(Miz Medi Hospital) Jung-Hyun Cho, M.D. (Miz Medi Hospital) Minimal Ovarian Stimulation.
IVF TROUBLESHOOTING ( Clinical Perspective) Malvin Emeraldi M. Luky, Dianing ASR,Muchsin J Family Fertility Center, RSIA Family Fatmawaty Hospital Jakarta,
Advantages of IUI Bipass (Vaginal acidity + cervical mucus hostility)
The place of IUI, especially in relation to IVF remains controversial. There are wide variations in indications, protocols of.
Endometrial biopsy in subfertile women undergoing intrauterine insemination (IUI) cycles improves pregnancy rates Tumanyan A, Tchzmachyan R, Grigoryan.
How IVF Protocols Work to Enhance the Success of IVF: Agonist vs Antagonist Dr Dimitrios Dovas MD Newlife IVF Greece.
The effect of intercourse on pregnancy rates in ovulation induction and intrauterine insemination cycles Akın Usta Çağla Bahar Hanedar Fatma Bahar Sunay.
Table 2. RCTs analyzed illustrating SET superiority over DET
Mannelijke subfertiliteit Wanneer IUI – IVF of ICSI
Mohamed Elmahdy MD. Lecturer Obs. Gyn. Alexandria University Egypt
Dr V Padmaja MBBS: Kakatiya medical college , wgl :1985
Özkan Özdamar, M.D., Assist. Prof.
Figure 1. Different factors that influence the higher cost of multiple pregnancies compared to singletons. PIH=pregnancy induced hypertension. HELLP=hemolysis,
The effect of the duration of stimulation on ART outcomes
Can we further reduce multiple pregnancies in Belgium?
טיפולי IVF בישראל: כמות מול איכות
No difference in cycle pregnancy rate and in cumulative live-birth rate between women with surgically treated minimal to mild endometriosis and women.
Ovarian stimulation protocols for IVF: is more better than less?
Ovulation Induction & IUI
Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.
Randomized comparison of different ovarian stimulation regimens for assisted reproductive technology in baboons (Papio anubis)  Atunga Nyachieo, M.Sc.,
How to do a study? Prof. P. Devroey.
Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement    Fertility and Sterility  Volume 102,
Thomas M. D’Hooghe, M. D. , Ph. D. , Bénédicte Denys, M. D
Intrauterine insemination with or without mild ovarian stimulation in couples with male subfertility due to oligo/astheno- and/or teratozoospermia or.
Stephanie A. Beall, M.D., Ph.D., Alan DeCherney, M.D. 
Fertility and Sterility
Presentation transcript:

Gonadotrofines en IUI moeten terugbetaald worden als eerstelijnsbehandeling bij Unexplained Infertility en Mild Male Subfertility  Thomas D’Hooghe, MD, PhD  Hoogleraar, Fac. Geneesk., K.U.Leuven  Coordinator Leuvens Univ Fertil Centrum

Current regulation reimbursement Gons, IVF and IUI in Belgium 1. Urinary FSH/LH (Menopur): 75% reimbursement -Fertility problems based on unsufficient endogenous stimulation of gonads -Controlled Ovarian Stimulation (COH) for Medically Assisted Reproduction (ART) 2. Recombinant FSH (Gonal-F, Puregon): -Same indications, -only reimbursed (75%) for indication COH and ART from 3 rd ART cycle onwards, if basal FSH less than 12 (measured at 2 different time periods during Early Foll Phase) 3. Laboratory reimbursement: IUI: none; IVF/ICSI: 1200 Euro if <43, 6 cycles lifetime

Current regulation reimbursement Gons, IVF and IUI in Belgium (2) 1. Urinary FSH/LH (Menopur): 75% reimbursement -Can be Prescribed by all gynecologists -Reimbursed for all patients for OI, IUI, IVF 2. Recombinant FSH (Gonal-F, Puregon): -Can be Prescribed by all gynecologists -Reimbursed only for IVF from 3 rd cycle onward 3. Cost for patient per IVF or per IUI cycle IVF (1200 Euro lab reimbursement): Euro IUI: (no lab reimbursement or K number): 350 Euro 4. Cost for society per IVF or per IUI cycle: Much higher for IVF than for IUI

REIMBURSEMENT GONS EUROPE IUIIVF/ICSI BELGIUM75% DENMARK50%75-85%, max 3 FINLAND50% FRANCE100% GERMANY50%, max 650%, max 4

REIMBURSEMENT GONS EUROPE IUIIVF/ICSI Netherlands0 %100%, c2-3 NorwayPartial Portugal40% SPAIN90%, MAX 690%, MAX 3 UK100% (Cond)

Why should reimbursement Gons in Belgium be reduced ? (1) 1. INCREASED COST PARTLY RELATED TO INCREASED CONSUMPTION, ESPECIALLY SINCE 1/7/2003 (MORE IVF) Total Million IU used per year (Source) Overall 2/3 IVF/ICSI and 1/3 OI/IUI  24.6  27.4 (+11%)  32.5 (+19%)  42.6 (+ 31%, reimbursement Lab IVF since 1/7/2003) 2. INCREASE IN TOTAL COST HIGHLY RELATED TO REPLACEMENT CHEAPER HUMEGON BY MORE EXPENSIVE MENOPUR IN 2001

Why should reimbursement Gons in Belgium be reduced ? (2) 2. PREVENTION OF MULTIPLE PREGNANCIES? ANALYSIS SPE NON-IVF: 6789 DELIVERIES, 743 TWINS (11%) 533 TWINS AFTER OI (7.8%) 210 TWINS AFTER IUI (3.1%) IVF: 5247 DELIVERIES, 1464 TWINS (28%) CONCLUSION: TWIN DELIVERY RATE 10X HIGHER AFTER IVF THAN AFTER IUI !!!

Why should reimbursement Gons in Belgium be reduced ? (3) 2. PREVENTION OF MULTIPLE PREGNANCIES? ANALYSIS SPE ALL MULTIPLE DELIVERIES ANALYZED (N=2207) IUI: 210/2207 (9.5%) OI: 533/2207 (24.1%) IVF/ICSI: 1464/2207 (66.3%) CONCLUSION: IVF RESPONSIBLE FOR 2/3 OF ALL MULTIPLE DELIVERIES IUI RESPONSIBLE FOR LESS THAN 10% !!!

Why should reimbursement Gons in Belgium be reduced ? (4) STRATEGY TO REDUCE N MULTIPLE PREGNANCIES AFTER IVF (2/3 OF ALL MULTIPLE PREGNANCIES) -LIMITED N OF EMBRYOS FOR ET (EFFECT: 28% TO ??) ! LIMIT REIMBURSEMENT OF GONS TO MAX 6 CYCLES, MAX 2500 IU PER CYCLE, AGE<43 YRS, LIFETIME = FINANCIAL ISSUE, NOT PREVENTION STRATEGY FOR MULTIPLE BIRTHS

Why should reimbursement Gons in Belgium be reduced ? (5) STRATEGY TO REDUCE N OF MULTIPLE PREGNANCIES: NON-IVF: BOTH OI (25% MULTIPS) AND IUI (9% MULTIPS) CONSENSUS PROPOSAL VWRG-VVOG-GGOL (MINISTER F VANDENBROUCKE) = LIMIT REIMBURSEMENT OF GONS TO MAX 6 CYCLES, MAX 1200 IU PER CYCLE, AGE<43 YRS, LIFETIME = PREVENTION STRATEGY (LOW DOSE STEP UP) WITH SECONDARY COST REDUCTION

9 REASONS FOR GONS TO BE REIMBURSED FOR COH AND IUI  COH AND IUI WORKS. EVIDENCE BASED FIRST LINE OF TREATMENT FOR MILD MALE SUBFERTILITY AND FOR UNEXPLAINED INFERTILITY  GONADOTROPHINS + IUI AT LEAST TWICE AS SUCCESSFUL AS CLOMIPHENE CITRATE + IUI  COH AND IUI RESPONSIBLE FOR LESS THAN 10% OF ALL MULTIPLE (ART) DELIVERIES IN FLANDERS  MULTIPLE PREGNANCY RATE NOT NECESSARILY HIGHER AFTER GONS + IUI THAN AFTER CC + IUI  PREVENTION OF MULTIPLE PREGNANCIES TO LESS THAN 10% PER CYCLE IS POSSIBLE USING LOW DOSE STEP-UP PROTOCOL, ULTRASOUND MONITORING, SELECTIVE FOLLICULAR ASPIRATION OR IVF OR CYCLE CANCELLATION

9 REASONS FOR GONS TO BE REIMBURSED FOR COH AND IUI  SAFER THAN IVF: NO EVIDENCE OF INCREASED MORBIDITY SINGLETON PREGNANCIES, UNLIKE IVF  MORE COST-EFFECTIVE THAN IVF. If Gons only reimbursed for IVF, treatment with COH and IUI will become so expensive, that IVF will become the first line of treatment for all infertility with not only increased cost but also increased multiple pregnancies 8.FREEDOM OF CHOICE FOR PATIENT TO CHOOSE COH AND IUI AS AN EFFECTIVE BUT MORE NATURAL, LESS INVASIVE, LOWER DOSED TREATMENT THAN IVF 9.FREEDOM OF CHOICE FOR GYNECOLOGIST, ALSO THOSE WORKING OUTSIDE A OR B CENTRES

REASON 1: EVIDENCE BASED  MILD MALE SUBFERTILITY: COHLEN, COCHRANE LIBRARY 2002, UPDATED GOI 2004 COH + IUI BETTER THAN NATURAL CYCLE + TI (OR 6.2) COH + IUI BETTER THAN COH + TI (OR 2.1), BUT ONLY TRUE FOR GONS NOT FOR CLOMIPHENE COH + IUI BETTER THAN NATURAL CYCLE + IUI (OR 2), BUT ONLY TRUE FOR GONS, NOT FOR CLOMIPHENE CONCLUSION: ONLY GONS, NOT CLOMIPHENE ARE ADDED VALUE IN COMBINATION WITH IUI

REASON 1: EVIDENCE BASED 2. UNEXPLAINED INFERTILITY: META-ANALYSIS HUGHES 1997: INDEPENDENT POSITIVE EFFECT OF IUI (OR 2.8) AND GONS (OR 2.4) AND OF GONS + IUI (OR 5) META-ANALYSIS COHLEN, proceedings Doelen 2001; update GOI 2004 COH + IUI BETTER THAN COH + TI (OR 1.9) COH + IUI BETTER THAN NATURAL CYCLE + IUI (OR 1.9)

REASON 2: GONS + IUI MORE SUCCESSFUL THAN CC + IUI  MILD MALE SUBFERTILITY COHLEN, COCHRANE LIBRARY 2002, UPDATED GOI 2004 COH + IUI BETTER THAN COH + TI (OR 2.1), BUT ONLY TRUE FOR GONS NOT FOR CLOMIPHENE COH + IUI BETTER THAN NATURAL CYCLE + IUI (OR 2), BUT ONLY TRUE FOR GONS, NOT FOR CLOMIPHENE CONCLUSION: ONLY COH AND IUI WITH GONS, NOT CLOMIPHENE IS EVIDENCE BASED TREATMENT FOR MALE SUBFERTILITY

REASON 2: GONS + IUI MORE SUCCESSFUL THAN CC + IUI 2. UNEXPLAINED INFERTILITY: META-ANALYSIS HUGHES 1997: INDEPENDENT POSITIVE EFFECT OF IUI (OR 2.8) AND GONS (OR 2.4) AND OF GONS + IUI (OR 5) NO INDEPENDENT POSITIVE EFFECT OF CLOMIPHENE

REASON 2: GONS + IUI MORE SUCCESSFUL THAN CC + IUI 3. META-ANALYSIS COHLEN 2004 (IN PRESS, GOI) 4 RCTS COMPARING GONS AND CLOMIPHENE (UNEXPL INFERT, MALE, DONOR) (Karlstrom, Balasch, Ecochard, Matorras) PREGNANCY RATE: GONS 13% (48/373) CLOMIPHEN 6% (27/428) OR 2.2

REASON 2: GONS + IUI MORE SUCCESSFUL THAN CC + IUI 4. ADVISE EXPERT COMMISSION NETHERLANDS (TFO, 2004) 13 experts in reproductive medicine QUALITY INDICATORS FOR IUI: Amongst others: -6 cycles (male subfertility, unexplained subfert) -Gons for COH, Clomiphene not recommended -Start Gons at 75 IU per day -Increase dose Gons with increments of 37.5 IU per day

REASON 3: COH + IUI ONLY RESPONSIBLE FOR MINORITY OF MULTIPLE PREGNANCIES (ART) ANALYSIS SPE ALL MULTIPLE DELIVERIES ANALYZED (N=2207) IUI: 210/2207 (9.5%) OI: 533/2207 (24.1%) IVF/ICSI: 1464/2207 (66.3%) CONCLUSION: IVF RESPONSIBLE FOR 2/3 OF ALL MULTIPLE DELIVERIES IUI RESPONSIBLE FOR LESS THAN 10%

REASON 4: MULTIPLE PREGNANCY RATE NOT NECESSARLY HIGHER AFTER GONS + IUI VS CC + IUI 1. META-ANALYSIS COHLEN 2004 (IN PRESS, GOI) 4 RCTS COMPARING GONS AND CLOMIPHENE (UNEXPL INFERT, MALE, DONOR) (Karlstrom, Balasch, Ecochard, Matorras); ONLY Balasch and Matorras with Multip Data MULTIPE PREGNANCY RATE/PREGNANCY: GONS 14% (6/42) CLOMIPHEN 10% (2/10) NS

REASON 4: MULTIPLE PREGNANCY RATE NOT NECESSARLY HIGHER AFTER GONS + IUI VS CC + IUI 2. RCTS PROVING THAT HIGH SUCCES CAN BE MAINTAINED USING LOW DOSE STEP-UP GONS + IUI - Spiessens et al 2003: RCT soft tip vs hard tip IUI catheter Preg Rate/IUI cycle: 20% (54/267) vs 19% (50/269) Multiple Birth Rate/pregnancy 4% (2/54) vs 6% (3/50) - Ragni et al, 2004: 50 IU FSH daily + GnRH antagonist + IUI: Preg Rate /initiated IUI cycle: 34% Multiple Pregnancy Rate: 0%

REASON 4: MULTIPLE PREGNANCY RATE NOT NECESSARLY HIGHER AFTER GONS + IUI VS CC + IUI 3. Retrospective studies. Dickey et al, 2001, 3608 cycles, Multiple Implantation Rate per Pregnancy CC: 17/176 or 10% Gon: 33/179 or 18% Multiple Live Birth Rate per Total Live Births: CC: 12/127 or 9.4% (twins) Gon: 19/79 or 24% (20% twins and 4% triplets)

REASON 4: MULTIPLE PREGNANCY RATE NOT NECESSARLY HIGHER AFTER GONS + IUI VS CC + IUI 3. Retrospective studies. -Spiessens, Castelain and D’Hooghe, 2004, 2423 cycles, database LUFC Overall LBR/IUI 12.5%; Overall Multiple LBR/Total LB: 11% LB/ IUI MLB/ LB ALL % 303/ % 34/303 CC 653 9% 61/ % 9/61 Gons % 234/ % 25/234

REASON 4: MULTIPLE PREGNANCY RATE NOT NECESSARLY HIGHER AFTER GONS + IUI VS CC + IUI 3. Retrospective studies. Spiessens, Castelain and D’Hooghe, 2004, 2423 cycles, database LUFC MONOFOLLICULAR GROWTH (n=1170) LBR/ IUI MLB/ LB CC % 27 11% 3 Gons % % 4

REASON 4: MULTIPLE PREGNANCY RATE NOT NECESSARLY HIGHER AFTER GONS + IUI VS CC + IUI CONCLUSION BASED ON CURRENT EVIDENCE: Multiple Preg (LB) /Total Preg (LB) 1.RCTS: CC (10%) = Gon (14%) 2.Low dose step up protocols: 0-6% (Ragni et al, 2004; Spiessens et al, 2003) 3.Retrospective studies: variable according to center and stimulation/monitoring style LUFC ( ): Gon 11%; Clomiphene 15% Dickey ( ): Gon 24%; Clomiphen 9.4%

REASON 5: PREVENTION OF MULTIPLE PREGNANCY RATE POSSIBLE USING GONS + IUI LEUVEN GUIDELINES FOR COH WITH GONS AND IUI:  LOW DOSE STEP UP (50 OR 75 iu)  ULTRASOUND MONITORING (AVAILABLE ON DAILY BASIS)  OBJECTIVE: MONOFOLLICULAR DEVELOPMENT,  IF 2 DOMINANT FOLLICLES: DISCUSS WITH PATIENT  IF MORE THAN 2 FOLLICLES OF 14 MM OR MORE: -SELECTIVE FOLLICULAR ASPIRATION (SHOULD BE AVAILABLE) -GO TO IVF -CANCEL CYCLE AND NO SEXUAL INTERCOURSE

4 OTHER REASONS FOR GONS TO BE REIMBURSED FOR COH+IUI  SAFER THAN IVF: NO EVIDENCE OF INCREASED MORBIDITY SINGLETON PREGNANCIES, UNLIKE IVF  MORE COST-EFFECTIVE THAN IVF. If Gons only reimbursed for IVF, treatment with COH and IUI will become so expensive, that IVF will become the first line of treatment for all infertility with not only increased cost but also increased multiple pregnancies 8.FREEDOM OF CHOICE FOR PATIENT TO CHOOSE COH AND IUI AS AN EFFECTIVE BUT MORE NATURAL, LESS INVASIVE, LOWER DOSED TREATMENT THAN IVF 9.FREEDOM OF CHOICE FOR GYNECOLOGIST, ALSO THOSE WORKING OUTSIDE A OR B CENTRES

VOTE FOR VWRG-VVOG-GGOLF PROPOSAL REIMBURSEMENT GONS AND IUI MUST BE GUARANTEED BUT LIMITED TO PREVENT MULTIPLE PREGNANCIES (SECONDARY EFFECT: COST REDUCTION) 1.MAX 6 CYCLES, MAX 1200 IU/CYCLE, <43 YRS, LIFETIME 2.ONLY TO BE PRESCRIBED BY GYNECOLOGISTS WORKING IN OR AFFILIATED WITH A RECOGNIZED A OR B CENTER 3.IUI SHOULD BE RECOGNIZED WITH A K NUMBER 4.PROSPECTIVE REGISTRATION PR AND MULTIP PR VIA COLLEGE PHYSICIANS REPRO MED